[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652224":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":18,"armGroups":27,"interventions":40,"overallOfficials":49,"centralContacts":53,"locations":59,"responsibleParty":76,"collaborators":18,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":18,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":18,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":18,"overallStatus":62,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Pakistan Institute of Medical Sciences","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Change in Clinical Severity Score from Baseline to 72 Hours","Change in the study-defined Clinical Severity Score from baseline at hospital admission to 72 hours after initiation of treatment. The score ranges from 0 to 12 and is calculated from heart rate, wheezing, respiratory rate, dyspnea, respiratory support, and feeding difficulties, with each component scored from 0 to 2. Higher scores indicate greater clinical severity. The change in score will be compared between the montelukast and placebo groups","Baseline (hospital admission) and 72 hours after initiation of treatment",[14],{"measure":15,"description":16,"timeFrame":17},"Length of Hospital Stay","Length of hospital stay measured in hours from hospital admission until hospital discharge. Discharge is defined by resolution of symptoms, including improved feeding, absence of respiratory distress, a clinical severity score less than 3, and respiratory rate within the normal range for age.","From baseline (hospital admission;day 1) through hospital discharge ( day 7)",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":18,"whoMasked":25},"SINGLE",[26],"PARTICIPANT",[28,34],{"label":29,"type":30,"description":31,"interventionNames":32},"Montelukast","EXPERIMENTAL","Participants will receive montelukast 4 mg sachet orally once daily at night in addition to standard supportive care for acute bronchiolitis.",[33],"Drug: Montelukast",{"label":35,"type":36,"description":37,"interventionNames":38},"Control","PLACEBO_COMPARATOR","Participants will receive placebo sugar granules orally once daily at night according to the same schedule as the montelukast group, in addition to standard supportive care for acute bronchiolitis",[39],"Drug: Placebo",[41,45],{"type":42,"name":29,"description":43,"armGroupLabels":44,"otherNames":18},"DRUG","Administrating montelukast to experimental group and monitoring response",[29],{"type":42,"name":46,"description":47,"armGroupLabels":48,"otherNames":18},"Placebo","Placebo sugar granules administered orally once daily at night according to the same schedule as montelukast 4 mg sachet, in addition to standard supportive care for acute bronchiolitis",[35],[50],{"name":51,"affiliation":5,"role":52},"Dr Haniyah Anwar","PRINCIPAL_INVESTIGATOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":18,"email":58},"Dr Haniyah Anwar, M.B.B.S","CONTACT","+92334-8359647","haniyahanwar@yahoo.com",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Pakistan Institute of Medical Sciences, Islamabad","RECRUITING","Islamabad","Federal","44000","Pakistan","PK",{"type":69,"coordinates":70},"Point",[71,72],73.04329,33.72148,{"lat":72,"lon":71},[75],{"name":55,"role":56,"phone":57,"phoneExt":18,"email":58},{"type":52,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Haniyah Anwar","Post Graduate Trainee, Children Hospital, PIMS","100652224","phase-2-evaluating-the-role-of-montelukast-in-management-of-acute-bronchiolitis-100652224",false,"NCT07770464","Evaluating The Role Of Montelukast In Management Of Acute Bronchiolitis","Inclusion Criteria\n\n* Age 4 weeks to 2 years\n* Both genders\n* Duration of respiratory symptoms less than 4 days\n* Clinical diagnosis of acute bronchiolitis according to the operational definition provided in the study protocol\n\nExclusion Criteria\n\n* History of asthma\n* Previous hospital admissions for respiratory illness\n* Use of asthma medications\n* Congenital heart disease\n* Bronchopulmonary dysplasia\n* Immunodeficiency\n* Immunosuppression\n* Radiological evidence of pneumonia, including infiltrates or patches on chest X-ray","ALL","4 Weeks","2 Years",{"count":89,"type":90},60,"ESTIMATED","INTERVENTIONAL",[93],"PHASE2","This study aims to evaluate the role of Montelukast in management of acute Bronchiolitis in indoor patient and how this drug shortens the duration of admission and improves symptoms",[96],"Acute Bronchiolitis","2026-08-17",{"date":99,"type":100},"2026-08-18","ACTUAL",{"date":102,"type":100},"2026-01-01",{"date":104,"type":90},"2026-09-30",{"name":5,"class":6},1]